MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) Medical Center in Bronx, New York. The first participant consented to participation on November 8, 2021. The study is currently open for enrollment and will treat up to 60 participants over 2-3 years.
First Participant Consented to Participation in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Psychotherapy in U.S. Military Veterans with Chronic PTSD
